Opinion|Videos|April 16, 2025
Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing
Author(s)Caron A. Jacobson, MD, MMSc, Peter Riedell, MD
Experts discuss novel combination therapies in first-line chronic lymphocytic leukemia (CLL) and their potential impact on treatment sequencing and patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.
Advertisement
Advertisement
Trending on OncLive
1
Revisit Every OncLive On Air Episode From June 2026
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
FDA Flashback: Breast Cancer Decisions and News From June 2026
4
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
5